



The Cyclodextrin Company

Cyclodextrin – protein interactions

Practical aspects



Cyclodextrins are molecular containers. As of 2017, 61 products of small molecules are formulated with CDs.









prostavasin*















Biological active substances (big molecules), proteins, peptides, monoclonal antibodies gained immerse interest in product development recently

Human Insulin



Peptide hormone 5808 Da



Monoclonal antibodies ~1300 amino acids, 150 000 Da ³



Why to use CDs in protein and biological formulations:

- Safer than most current excipients (e.g. Tween) no peroxide formation, corresponding immunogenicity, degradation
- Prevention of aggregation, delay folding
- Less protein adsorption onto container surface
- Reduce/maintain viscosity
- Improve injectability
- Physical and chemical stabilization of proteins
- Life-cycle management



Cyclolab has recently been putting immerse efforts to develop cyclodextrins that are particularly suitable for excipients in protein formulations.


During these studies, several therapeutically relevant model compounds are included, yet we are open to test how well our CDs fit your particular monoclonal antibody or other type of protein.



Outcomes of protein aggregation


- Decreased efficiency
- Altered pharmacokinetics
- Immunogenicity, irritation, anaphylaxis
- Short shelf-life, poor stability

mABs are
particularly
prone to
aggregation





Cyclodextrins are able to interact with proteins and polypeptides on several levels. The classical inclusion involves aromatic amino acids






Main characteristics of the CD-protein interactions are:


- CDs attract to hydrophobic regions of the proteins
- The interactions are host-guest and electrostatic type
- CDs act like artificial chaperons
- Certain CDs act like chaotropic agents and delay protein-protein interaction and thereby folding in solution




Cyclodextrin's effect on peptide aggregation

TT-232, heptapeptide






Without additive




With DIMEB-CD



Cyclodextrin's effect on insulin aggregation






insulin hexamer

1. Control, 2. Stirred without CD, 3. HPBCD, 4. alfa-CD, 5. beta-CD, 6. gamma-CD



Cyclodextrin's effect on Ig B aggregation



Turbidity of 1.8 mg/mL IgGB aqueous solution after 1 h stirring

Hartl (2013)



Cyclodextrins or TWEEN?

- Tween-like detergents efficiently prevent protein aggregation, prevent immunogenicity
- Polysorbate 80 is the most common, they are widely used
- However, their degradataion leads to aldehydes, epoxy-acids and peroxides damaging proteins

12



Active

porcine insulin zinc

muromonab-CD3

pegaspargase

Shelf Life

42 days

Product

Vetsulin

NovoLog

Oncaspar

ORTHOCLONE

Cyclodextrin – protein interactions

Ingredients

Some protein based products, their shelflives and additives

Remicade	infliximab	3 years at 2 °C−8 °C.	dibasic sodium phosphate dihydrate, monobasic sodium phosphate monohydrate, polysorbate 80, and sucrose. No preservatives are present.
Humira	Adalimumab	2 years at 2 °C − 8 °C.	sodium chloride, monobasic sodium phosphate dihydrate, dibasic sodium phosphate dihydrate, sodium citrate, citric acid monohydrate, mannitol, polysorbate 80 and water for injections
Herceptin	trastuzumab	4 years at 2 °C − 8 °C.	histidine hydrochloride, histidine, trehalose dihydrate, polysorbate 20

insulin aspart

28 days

glycerin, phenol, metacresol, zinc, disodium hydrogen phosphate dihydrate, sodium chloride and water for injection

9 months

polysorbate 80 water

dibasic sodium phosphate dihydrate, dibasic sodium phosphate heptahydrate, sodium chloride, water for injection

zinc chloride, methylparaben, sodium chloride, sodium acetate, water

sodium phosphate, monobasic sodium phosphate, dibasic sodium chloride



Cyclodextrins and mAbs

mAb: polyionic protein with hydrophobic surfaces

- •The hydrophobic surface induces aggregation
- •The net surface charge is minimal at pH 5 7.5 \rightarrow no electrostatic repulsion

Consequence: mAb-mAb aggregation increases

- •Cyclodextrin masking of the hydrophobic surface reduces van der Waals interactions
- •Increase in the surface charge increases electrostatic repulsion

Result: mAb-mAb aggregation decreases



Company contacts:

CycloLab Cyclodextrin Research & Development Laboratory Ltd.

Budapest, P.O. Box 435, H-1525 Hungary

Location: Illatos út 7., Budapest, H-1097 Hungary

TEL: (+36) 1-347-60-60 or -70; FAX: (+36) 1-347-60-68

E-mail: info@cyclolab.hu; Homepage: http://cyclolab.hu/

Contact person: Tamas Sohajda

R&D Director

<u>info@cyclolab.hu</u> Tel: (+36) 1-347-60-72